X
Pharma Advancement
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development

    New Delivery Path Brings To Light Efficacy of Immunotherapy

    Nasal Spray Shows Its Effect Against New COVID Variants

    Mid-Point Regulatory Science Strategy Study Published By EMA

    AADC Inadequacy To Be Handled By A Novel Gene Therapy

    New Drug Explored For Epilepsy Gets $3M Funding In Australia

    Care Access Research Launches Alliance to Provide Infrastructure for COVID-19 Trials

    Faster Clinical Trial Nods Planned By The UK To Curb Issues

    Pharma Drugs Gain From Tardigrade Proteins, Says Research

    Pharma Drugs Gain From Tardigrade Proteins, Says Research

    U.S. FDA Approves DARZALEX Split-Dosing Regimen

    EMA Keeping A Close Watch On Critical Medicine Shortages

    Pathways Laid Down By The CMS For Drug Price Negotiations

    Pathways Laid Down By The CMS For Drug Price Negotiations

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development

    New Delivery Path Brings To Light Efficacy of Immunotherapy

    Nasal Spray Shows Its Effect Against New COVID Variants

    Mid-Point Regulatory Science Strategy Study Published By EMA

    AADC Inadequacy To Be Handled By A Novel Gene Therapy

    New Drug Explored For Epilepsy Gets $3M Funding In Australia

    Care Access Research Launches Alliance to Provide Infrastructure for COVID-19 Trials

    Faster Clinical Trial Nods Planned By The UK To Curb Issues

    Pharma Drugs Gain From Tardigrade Proteins, Says Research

    Pharma Drugs Gain From Tardigrade Proteins, Says Research

    U.S. FDA Approves DARZALEX Split-Dosing Regimen

    EMA Keeping A Close Watch On Critical Medicine Shortages

    Pathways Laid Down By The CMS For Drug Price Negotiations

    Pathways Laid Down By The CMS For Drug Price Negotiations

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home Market Moves

Sanofi to invest Rs 460 crore to make insulin in India

Yuvraj_pawp by Yuvraj_pawp
30th January 2015
in Market Moves

French pharma major Sanofi is investing Rs 460 crore to set up a new insulin facility in Hyderabad and augment its capacity to produce Insuman, its human insulin product. The new facility will have the capacity to manufacture up to 60 million cartridges a year and will enable Shantha Biotechnics, the wholly owned subsidiary of Sanofi in India, to cater to emerging markets, including India.

Located in Muppireddipalli on the outskirts of Hyderabad, it will be Sanofi’s second plant apart from the one in Frankfurt, Germany. Telangana Chief Minister K Chandrasekhar Rao laid the foundation stone for the facility on January 29.

According to Harish Iyer, CEO, Shantha Biotechnics, the construction of the 13,500 sq m building will begin immediately. “It will be operational by 2019,” he said. The new facility, Iyer said, is being set up under technology transfer within Sanofi. It will enable Shantha Biotechnics to make insulin in cartridge format for the first time. The insulin formulation will be made in the new facility but the bulk (powder) to make the product will continue to be imported from Germany.

Shantha Biotechnics was acquired by Sanofi in 2009. It was a company founded by KI Varaprasad Reddy, who is currently its non-executive chairman. A press release put out by Shantha Biotechnics says that while Sanofi’s Frankfurt facility will continue to manufacture Insuman, the new facility will address local demand. In the long run, it could even emerge as Sanofi’s injectables’ hub for emerging market.

Shailesh Ayyangar, Managing Director, India and Vice-President, South Asia, Sanofi, says in the company release: “By setting up a manufacturing site at Shantha Biotechnics for our diabetes product Insuman, Sanofi is a front-runner in its endeavour of addressing the growing epidemic of diabetes in India.

Furthermore, the technology transfer and a successful collaborative effort within the Sanofi Group underline our commitment to investing and ‘making in India’. We look forward to the successful completion of the Insuman site construction, so that many more diabetic patients in India can have easier access to better disease management and quality of life.”

Previous Post

Integrated Role Of Nutrition Post-Hospital Discharge: Summary Of A Scientific Roundtable Discussion

Next Post

Pfizer to Acquire Hospira

Related Posts

Featured

SVB Collapse And Its Implications On Biotechnology Sector

18th March 2023
Featured

US President Looks To Double The Drugs For Price Negotiation

18th March 2023
$118bn Sales By 2026 Is What Japanese Pharma Can Expect
Featured

$118bn Sales By 2026 Is What Japanese Pharma Can Expect

2nd March 2023
Featured

Bioavailability Enhancement Market Projects CAGR of 11%

28th February 2023
Grünenthal to buy NebidoTM testosterone treatment from Bayer for €500m
Market Moves

Grünenthal to buy NebidoTM testosterone treatment from Bayer for €500m

18th July 2022
Could The Long Deckline In Biotechnology M&A Be Ending
Featured

Could The Long Deckline In Biotechnology M&A Be Ending

16th July 2022
Next Post

Pfizer to Acquire Hospira

Latest News

Drug Development

New Delivery Path Brings To Light Efficacy of Immunotherapy

1st April 2023
Cathay Cargo signs global airline partnership with Tower Cold Chain
Packaging & Logistic

Cathay Cargo signs global airline partnership with Tower Cold Chain

31st March 2023
Quotient Sciences completes integration of drug substance into Translational Pharmaceutics Platform
Facilities & Operation

£277m Funding Set To Benefit UK Life Sciences Manufacturing

31st March 2023
Drug Development

Nasal Spray Shows Its Effect Against New COVID Variants

27th March 2023
FDA Approvals

Mid-Point Regulatory Science Strategy Study Published By EMA

27th March 2023
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack

System

  • Search
  • Sitemap
  • RSS Feed

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In